| Literature DB >> 20700121 |
M Rutegård1, H Nordenstedt, Y Lu, J Lagergren, P Lagergren.
Abstract
BACKGROUND: There is an unexplained male predominance in the incidence of oesophageal adenocarcinoma, and the sex-specific distribution of its risk factors in the general population is not known.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20700121 PMCID: PMC2938252 DOI: 10.1038/sj.bjc.6605804
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Sex-specific prevalence rates and results of logistic regression analyses
|
|
|
| |
|---|---|---|---|
|
|
|
|
|
|
| |||
| No | 2711 (84.2) | 1301 (77.2) | 1.00 (reference) |
| Yes | 330 (10.2) | 227 (13.5) | 0.70 (0.58–0.84) |
| | |||
|
| |||
| <25 (normal weight) | 1120 (34.8) | 790 (46.9) | 1.00 (reference) |
| 25–30 (overweight) | 1508 (46.8) | 538 (31.9) | 1.98 (1.72–2.27) |
| ⩾30 (obese) | 435 (13.5) | 254 (15.1) | 1.22 (1.01–1.47) |
|
| |||
|
| |||
| Never smoker | 1459 (45.3) | 890 (52.8) | 1.00 (reference) |
| Former smoker | 1210 (37.6) | 480 (28.5) | 1.50 (1.30–1.72) |
| Current smoker | 445 (13.8) | 233 (13.8) | 1.18 (0.98–1.42) |
| | |||
|
| |||
| >12 years | 771 (23.9) | 475 (28.2) | 1.00 (reference) |
| 9–12 years | 397 (12.3) | 119 (7.1) | 2.10 (1.65–2.68) |
| ⩽9 years | 1953 (60.7) | 1034 (61.3) | 1.07 (0.92–1.24) |
| | |||
|
| |||
| Daily | 608 (18.9) | 356 (21.1) | 1.00 (reference) |
| Weekly | 216 (6.7) | 170 (10.1) | 0.83 (0.64–1.06) |
| Monthly | 217 (6.7) | 156 (9.3) | 0.89 (0.68–1.15) |
| No use | 2023 (62.8) | 926 (54.9) | 1.35 (1.14–1.59) |
| | |||
Abbreviations: CI=confidence interval; N=number; NSAID=non-steroidal anti-inflammatory drug; OR=odds ratio; SES=socioeconomic status.
Sex-specific prevalence rates and results of logistic regression analyses with OR and 95% CIs values in a randomly selected sample of 4906 Swedish citizens, using risk factors as exposures and male sex as outcome.
Adjusted for age, physical activity, reflux, education, body mass index, smoking status, NSAID use.
Defined as at least weekly symptoms of acid regurgitation and/or heartburn and/or weekly use of gastro-oesophageal reflux disease treatment, such as proton pump inhibitors, antacids, or H2-blockers.
No use or less than once a month.
Sex-specific prevalence rates and results of logistic regression analyses
|
|
|
| |
|---|---|---|---|
|
|
|
|
|
| Reflux-negative, BMI<25 | 965 (30.0) | 645 (38.3) | 1.00 (reference) |
| Reflux-positive, BMI⩾25 | 211 (6.6) | 139 (8.2) | 0.98 (0.77–1.24) |
| Reflux-negative, BMI<25, never smoker | 482 (15.0) | 334 (19.8) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, ever smoker | 117 (3.6) | 62 (3.7) | 1.27 (0.90–1.78) |
| Reflux-negative, BMI<25, education >9 years | 424 (13.2) | 293 (17.4) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, education⩽9 years | 131 (4.1) | 88 (5.2) | 0.90 (0.66–1.24) |
| Reflux-negative, BMI<25, ever use of NSAIDs | 267 (8.3) | 204 (12.1) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, never use of NSAIDs | 97 (3.0) | 45 (2.7) | 1.62 (1.09–2.42) |
| Reflux-negative, BMI<25, never smoker, education >9 years | 244 (7.6) | 160 (9.5) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, ever smoker, education ⩽9 years | 72 (2.2) | 36 (2.1) | 1.17 (0.74–1.83) |
| Reflux-negative, BMI<25, never smoker, ever use of NSAIDs | 120 (3.7) | 113 (6.7) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, ever smoker, never use of NSAIDs | 50 (1.6) | 18 (1.1) | 2.59 (1.42–4.72) |
| Reflux-negative, BMI<25, education >9 years, ever use of NSAIDs | 95 (3.0) | 86 (5.1) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, education ⩽9 years, never use of NSAIDs | 60 (1.9) | 27 (1.6) | 1.79 (1.04–3.10) |
| Reflux-negative, BMI<25, education >9 years, ever use of NSAIDs, never smoker | 47 (1.5) | 47 (2.8) | 1.00 (reference) |
| Reflux-positive, BMI⩾25, education ⩽9 years, never use of NSAIDs, ever smoker | 31 (1.0) | 10 (0.6) | 2.76 (1.21–6.32) |
Abbreviations: BMI=body mass index; CI=confidence interval; N=number; NSAID=non-steroidal anti-inflammatory drug; OR=odds ratio; SES=socioeconomic status.
Sex-specific prevalence rates and results of logistic regression analyses with OR and 95% CIs values, in a randomly selected sample of 4906 Swedish citizens, using predefined combinations of risk factors as exposures and male sex as outcome.
Using male sex as outcome and adjusted for age only.
Gastro-oesophageal reflux disease, defined as at least weekly symptoms of acid regurgitation and/or heartburn and/or weekly use of reflux treatment such as proton pump inhibitors, antacids, H2-blockers, etc.
Age-stratified sex-specific prevalence rates and results of logistic regression analyses
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| ||||||
| No | 1319 (86.8) | 716 (82.8) | 1.00 (reference) | 1392 (81.8) | 585 (71.3) | 1.00 (reference) |
| Yes | 147 (9.7) | 112 (12.9) | 0.70 (0.53–0.92) | 183 (10.8) | 115 (14.0) | 0.69 (0.53–0.90) |
|
| ||||||
| <25 (normal weight) | 513 (33.8) | 453 (52.4) | 1.00 (reference) | 607 (35.7) | 337 (41.0) | 1.00 (reference) |
| 25–30 (overweight) | 734 (48.3) | 269 (31.1) | 2.41 (1.99–2.93) | 774 (45.5) | 269 (32.8) | 1.63 (1.33–1.99) |
| ⩾30 (obese) | 219 (14.4) | 110 (12.7) | 1.74 (1.33–2.29) | 216 (12.7) | 144 (17.5) | 0.87 (0.67–1.13) |
|
| ||||||
| Never | 700 (46.1) | 405 (46.8) | 1.00 (reference) | 759 (44.6) | 485 (59.1) | 1.00 (reference) |
| Former smoker | 522 (34.4) | 281 (32.5) | 1.04 (0.86–1.27) | 688 (40.4) | 199 (24.2) | 2.18 (1.79–2.67) |
| Current smoker | 265 (17.4) | 154 (17.8) | 0.97 (0.76–1.24) | 180 (10.6) | 79 (9.6) | 1.41 (1.05–1.90) |
|
| ||||||
| >12 years | 460 (30.3) | 356 (41.2) | 1.00 (reference) | 311 (18.3) | 119 (14.5) | 1.00 (reference) |
| 9–12 years | 249 (16.4) | 89 (10.3) | 2.10 (1.58–2.80) | 148 (8.7) | 30 (3.7) | 2.14 (1.35–3.37) |
| ⩽9 years | 771 (50.8) | 399 (46.1) | 1.38 (1.13–1.67) | 1182 (69.5) | 635 (77.3) | 0.77 (0.61–0.98) |
|
| ||||||
| Daily | 608 (18.9) | 356 (21.1) | 1.00 (reference) | 441 (25.9) | 256 (31.2) | 1.00 (reference) |
| Weekly | 216 (6.7) | 170 (10.1) | 0.71 (0.48–1.05) | 110 (6.5) | 76 (9.3) | 0.85 (0.61–1.21) |
| Monthly | 217 (6.7) | 156 (9.3) | 0.71 (0.49–1.02) | 79 (4.6) | 37 (4.5) | 1.15 (0.74–1.78) |
| No use | 2023 (62.8) | 926 (54.9) | 1.26 (0.95–1.67) | 946 (55.6) | 388 (47.3) | 1.31 (1.07–1.61) |
Abbreviations: CI=confidence interval; N=number; NSAID=non-steroidal anti-inflammatory drug; OR=odds ratio; SES=socioeconomic status.
Age-stratified sex-specific prevalence rates and results of logistic regression analyses OR and 95% CIs values, in a randomly selected sample of 4906 Swedish citizens, using predefined combinations of risk factors as exposures and male sex as outcome.
Adjusted for physical activity, reflux, education, body mass index, smoking status, NSAID use.
Defined as at least weekly symptoms of acid regurgitation and/or heartburn and/or weekly use of gastro-oesophageal reflux disease treatment such as proton pump inhibitors, antacids, or H2-blockers.
No use or less than once a month.